Identification of pathogenic BRCA1 and BRCA2 variants is routinely used to predict risk of breast‐ and ovarian cancer and guide the use of risk reducing surgery, thus upfront genetic screening of all new breast cancer patients enables a more tailored surgical procedure 74, 75, 76, 77. Here, BRCA2 is linked to breast carcinoma.